The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease

Caspian Journal of Internal Medicine

Volumn 3, Issue 2, 2012, Pages 428-435

  Heidari, Behzad ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

COPD; CRP; ESR; Inflammation; Markers of inflammation

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; FIBRINOGEN; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LUNG FUNCTION; PATHOGENESIS; PNEUMONIA; PROGNOSIS; REVIEW;

EID: 84865299946     PISSN: 20086164     EISSN: 20086172     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008; 31: 1334-56.
2. Wouters E. COPD: from obstructive lung disease to chronic systemic inflammatory syndrome? Pneumologie 2009; 63: S107-12. [In German]
3. Sevenoaks MJ, Stockley RA. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype? Respir Res 2006; 7: 70.
4. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 2003; 112: 819-27.
5. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2007; 16: 236-40.
6. Heidari B, Heidari P, Tayebi ME. The value of changes in CRP and ESR for predicting treatment response in rheumatoid arthritis. APLAR J Rheumatol 2007; 10: 23-8.
7. Buess T, Ludwig C. Diagnostic value of C-reactive protein in comparison with erythrocyte sedimentation as routine admission diagnostic test. Schweiz Med Wochenschr 1995 28; 125: 120-4. [In German]
8. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 2008; 19: 104-8.
9. Kirdar S, Serter M, Ceylan E, et al. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest 2009; 69: 219-24.
10. Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C reactive protein in hospitalised adult patients with community acquired pneumonia, exacerbation or COPD. Chest 2011; 139: 1410-8.
11. Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin prognostic predictors in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009; 15: 120-5.
12. Sin DD, Man SF. Biomarkers in COPD. Are We There Yet? Chest 2008; 133: 1296-8.
13. Lee JY, Hwang SJ, Shim JW, et al. Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia. Korean J Lab Med 2010; 30: 406-13.
14. Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011; 139: 1410-8.
15. de Torres JP, Pinto-Plata V, Casanova C, et al. C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD. Chest 2008; 133: 1336-43.
16. Dahl M, Vestbo J, Lange P, et al. C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2007; 175: 250-5.
17. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867-74.
18. Broekhuizen R, Vernooy JH, Schols AM, Dentener MA, Wouters EF. Leptin as local inflammatory marker in COPD. Respir Med 2005; 99: 70-4.
19. Corsonello A, Pedone C, Battaglia S, et al. Creactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammation markers in elderly patients with stable chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr 2011; 53: 190-5.
20. Saetta M. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S17-20.
21. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-12.
22. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease .Eur Respir J 2003; 46: 5s-13s.
23. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849-53.
24. Patel AR, Hurst JR, Wedzicha JA. The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin Respir Crit Care Med 2010; 31: 267-75.
25. Piehl-Aulin K, Jones I, Lindvall B, Magnuson A, Abdel-Halim SM. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration 2009;78: 191-6.
26. Higashimoto Y, Yamagata Y, Taya S, et al. Systemic inflammation in COPD and asthma: similarities and differences. Nihon Kokyuki Gakkai Zasshi 2008; 46: 443-7. [In Japanese]
27. Ólafsdóttir IS, Góslason T, Thjódleifsson B, et al. Gender differences in the association between C-reactive protein, lung function impairment, and COPD. Int J Chron Obstruct Pulmon Dis 2007; 2: 635-42.
28. Wu SJ, Chen P, Jiang XN, Liu ZJ. C-reactive protein level and the correlation between lung function and CRP levels in patients with chronic obstructive pulmonary diseases. zhong Nan Da Xue Xue Bao Yi Xue Ban 2005; 30: 444-6. [In Chinese]
29. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, et al. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir Med 2009; 103: 1548-53.
30. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-9.
31. Bircan A, Gokirmak M, Kilic O, Ozturk O, Akkaya A. C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection. Med Princ Pract 2008; 17: 202-8.
32. Lacoma A, Prat C, Andreo F, et al. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6: 157-69.
33. Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008; 115: 225-32.
34. Kersul AL, Iglesias A, Rios A, et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2011; 47: 176-83.
35. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2006; 29: 527-34.
36. Osei-Bimpong A, Meck JH, Lewis SM. ESR or CRP? A comparison of their clinical utility. Hematology 2007; 12: 353-7.
37. Ukena C, Mahfoud F, Kindermann M, et al. The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. Int J Cardiol 2010; 145: 172-6.
38. Dahl M, Vestbo J, Zacho J, et al. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax 2010; 66: 197-204.
39. Sin DD, Man SF. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol 2007; 85: 141-7.
40. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension.Chest 2006; 13: 326-33.
41. Zhang YH, Guo LJ, Kuang TG, Zhu M, Liang LR. Association between the erythrocyte sedimentation rate, serum C-reactive protein and risk of lung cancer. Zhonghua Zhong Liu Za Zhi 2010; 32: 48-51. [In Chinese]
42. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-5.
43. Perng DW, Tao CW, Su KC, et al. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 2009; 33: 778-84.
44. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207-14.